Validity of Brain Metastasis Risk Predictive Model in Hormone Positive Breast Cancer Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorAssiut University
About this trial
This study aims to validate a prediction model of brain metastasis risk for females with HR+ breast cancer by using variables collected at diagnosis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Confirmed diagnosis of HR-positive primary invasive breast cancer.
Disqualifiers
Patients if they were diagnosed with brain metastases at the time of initial breast cancer diagnosis or within the subsequent three months.
Bilateral breast cancer.
Synchronic cancer (i.e., lung cancer, melanoma).
Paitents presenting neurologic symptoms without follow-up or lacking a contrast-enhanced magnetic resonance image (cMRI).
Trial population
Medical records of women with HR+ breast cancer in clinical oncology department in Assiut University Hospital, Assiut, Egypt.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
128 Participants
are grouped into 3 trial groupsGroup A: Low-risk group
Group B: Medium-risk group
Group C: High-risk group
Trial outcomes
Primary outcomes
1
Validity of prediction model of brain metastases risk for females with HR+ breast cancer
A Cox regression analysis to assess each group's risk of developing brain metastases. Adjusted hazard ratios (aHRs), 95 % CIs, and p values will be evaluated.
Time frame
2 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: